Page last updated: 2024-11-12

omdm-1 cpd

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

OMDM-1 cpd: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID10410511
CHEMBL ID1534468
SCHEMBL ID14106444
MeSH IDM0449986

Synonyms (26)

Synonym
NCGC00165853-01
omdm-1
omdm-1 cpd
(s)-n-oleoyltyrosinol
gtpl5721
(z)-n-[(2s)-1-hydroxy-3-(4-hydroxyphenyl)propan-2-yl]octadec-9-enamide
bdbm197168
omdm1
SCHEMBL14106444
9-octadecenamide, n-[(1s)-2-hydroxy-1-[(4-hydroxyphenyl)methyl]ethyl]-, (9z)-
ICDMLAQPOAVWNH-JRUKXMRZSA-N
(s)-n-(1-(4-hydroxyphenyl)-2-hydroxyethyl)oleamide
CHEMBL1534468
616884-62-9
HMS3648G15
omdm-1, >=97% (hplc), powder
omdm 1
Q27088836
SR-01000946214-1
sr-01000946214
F81789
CS-0082738
HY-121557
(s)-n-oleyl tyrosinol
(s)-n-(1-hydroxy-3-(4-hydroxyphenyl)propan-2-yl)oleamide
AKOS040733909
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (3)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency44.66840.003245.467312,589.2998AID2517
nuclear receptor ROR-gamma isoform 1Mus musculus (house mouse)Potency19.95260.00798.23321,122.0200AID2546
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Fatty acid-binding protein, liverMus musculus (house mouse)Ki0.04000.02100.34832.0000AID1802031
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (2)

Assay IDTitleYearJournalArticle
AID1345261Human GPR119 (GPR18, GPR55 and GPR119)2010Molecular endocrinology (Baltimore, Md.), Jan, Volume: 24, Issue:1
N-oleoyldopamine enhances glucose homeostasis through the activation of GPR119.
AID1802031FABP1 Fluorescent Ligand Displacement Assay from Article 10.1021/acs.biochem.6b00446: \\FABP1: A Novel Hepatic Endocannabinoid and Cannabinoid Binding Protein.\\2016Biochemistry, 09-20, Volume: 55, Issue:37
FABP1: A Novel Hepatic Endocannabinoid and Cannabinoid Binding Protein.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (13)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's10 (76.92)29.6817
2010's3 (23.08)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.64

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.64 (24.57)
Research Supply Index2.64 (2.92)
Research Growth Index4.27 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.64)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (7.69%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other12 (92.31%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]